RHHBF - Progenity Begins U.S. IPO Effort
Quick Take
Progenity (PROG) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement.
The firm is commercializing molecular testing products to maximize the ability to personalize disease treatments.
PROG is dealing with the temporary negative effects of the Covid-19 pandemic on its diagnostics business.
When we learn more about the IPO’s pricing and valuation, I’ll provide an update.
Company & Technology
San Diego, California-based Progenity was founded to develop advanced testing capabilities using genomics, epigenomics, proteomics and metabolomics to better inform and